Research 12 January 2026 - 21 May 2026

Lexaria Gets Attention with GLP-1 Test on Deck
····

Lexaria Gets Attention with GLP-1 Test on Deck

Lexaria Bioscience shares closed at $0.65 on Friday, up 7.33%, and resume Nasdaq trading Tuesday after the holiday. The company plans to start dosing in a human study comparing its DehydraTECH-semaglutide pills to Novo Nordisk’s Wegovy in mid-June. Lexaria extended a pharma partnership deal through the end of 2026. Its latest filing cited “substantial doubt” about ongoing operations without new funding.
May 26, 2026
BioVie Stock Pops After Parkinson’s Trial Milestone. The Real Test Comes in Q3
····

BioVie Stock Pops After Parkinson’s Trial Milestone. The Real Test Comes in Q3

BioVie shares closed at $1.35, up 3.05%, after the company said the last patient visit in its SUNRISE-PD Phase 2 Parkinson’s trial was completed. The company expects topline data in Q3 2026 for its experimental drug bezisterim. Trading volume was 19,735 shares, well below average. The trial enrolled 57 early-stage patients and tested motor and non-motor outcomes.
May 21, 2026
Google AI Overviews Accuracy Questioned Again as Study Points to Millions of Wrong Answers an Hour
···

Google AI Overviews Accuracy Questioned Again as Study Points to Millions of Wrong Answers an Hour

A New York Times analysis found Google’s AI Overviews answered factual questions correctly 91% of the time after switching to Gemini 3, but still produced millions of errors at scale. Google disputed the study’s methods and warned users to verify information. Some errors included basic facts, such as museum dates and hall of fame listings. The feature remains widely used, with over 2 billion monthly users.
April 14, 2026
Singapore’s S$1 billion AI research bet: new push to keep pace with U.S., China by 2030
···

Singapore’s S$1 billion AI research bet: new push to keep pace with U.S., China by 2030

Singapore will invest over S$1 billion in public AI research by 2030, officials announced Saturday. The plan targets basic research, industry applications, and talent development, with funds channeled to new research centres. Rising power and water costs linked to AI and data centre expansion were cited as concerns. The initiative forms part of the National AI Strategy 2.0.
January 24, 2026
Here’s what researchers reported, based on teens enrolled in the Adolescent Brain Cognitive Development (ABCD) Study:
·

Here’s what researchers reported, based on teens enrolled in the Adolescent Brain Cognitive Development (ABCD) Study:

Passive monitoring of 640 U.S. teens’ Android phones found average school-hour use at 1.16 hours daily, with social media apps most used. Older teens and those from lower-income households logged more time. Nearly all schools report smartphone policies, but the study shows high use persists. New Jersey and Kansas are moving to tighten enforcement, with New Jersey mandating phone restrictions statewide by 2026–27.
January 12, 2026

Stock Market Today

  • Top 2 ASX Shares to Buy and Hold for the Next Decade
    May 29, 2026, 8:30 PM EDT. Two ASX shares stand out for long-term growth potential: Lovisa Holdings Ltd (ASX: LOV) and the Global X S&P World Ex Australia GARP ETF (ASX: GARP). Lovisa, a fast-growing affordable jewellery retailer, is expanding its global footprint with a 6.3% store increase recently, boosted by strong 20% revenue and profit growth. Its valuation stands at under 19 times estimated FY28 earnings per share, signaling potential value. Meanwhile, the GARP ETF invests in 250 global companies with growth-at-a-reasonable-price traits, targeting firms with solid sales, earnings, attractive price/earnings ratios, and strong financial quality, positioning it for potential market-beating returns. These choices reflect solid growth and value strategies aimed at outperforming the S&P/ASX 200 Index over the next decade.